mailitics

Category: biotechnology

  • STAT+: National Resilience, startup hoping to reinvent drug manufacturing, to ‘wind down’ many of its facilities

    STAT+: National Resilience, startup hoping to reinvent drug manufacturing, to ‘wind down’ many of its facilities National Resilience, a startup that has raised over $2 billion by promising to transform drug manufacturing, said Monday that it would “wind down” many of its facilities.   But what remains of the firm has raised an additional $250 million…

  • STAT+: Up and down the ladder: The latest comings and goings

    STAT+: Up and down the ladder: The latest comings and goings Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is…

  • Opinion: STAT+: RFK Jr. acknowledges receiving unproven stem cell treatment from an Antigua clinic

    Opinion: STAT+: RFK Jr. acknowledges receiving unproven stem cell treatment from an Antigua clinic Welcome to Lab Dish, a First Opinion column on regenerative medicine from Paul Knoepfler. Health and Human Services Secretary Robert F. Kennedy Jr. recently revealed on a health influencer podcast that he received unproven stem cells at a clinic in Antigua…

  • GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds

    GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds People with diabetes who were taking GLP-1 drugs had a low but elevated risk of an age-related eye disease that can sometimes lead to blindness, a new observational study concludes, adding to a short list of concerns about eye health in…

  • STAT+: Taurine, a darling of longevity seekers, is found to be unreliable biomarker for aging

    STAT+: Taurine, a darling of longevity seekers, is found to be unreliable biomarker for aging Vijay Yadav warned people not to start downing taurine — an amino acid abundant in plants, animals and some energy drinks — just because his mice and monkey study suggested it might be an elixir for long life. But that…

  • An AI experiment at the FDA & Novo trailing in the obesity drug race

    An AI experiment at the FDA & Novo trailing in the obesity drug race On this week’s episode of “The Readout LOUD”: The Food and Drug Administration’s AI adventure, a deep look inside Novo Nordisk’s obesity stumble, and finally, another big M&A deal in biotech. The FDA has rolled out an internal AI tool called…

  • After groundbreaking CRISPR therapy, a homecoming

    After groundbreaking CRISPR therapy, a homecoming Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Baby KJ is back home! Also, we discuss the questionable efficacy of ctDNA blood tests, see what Vinay Prasad has to say at NORD, and more.  Read…

  • Pluvicto pushes earlier in prostate cancer play

    Pluvicto pushes earlier in prostate cancer play Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, STAT’s Matthew Herper chats with J&J’s R&D chief, we see the radiopharmaceutical Pluvicto being considered earlier for prostate cancer, and more.  Read the rest… Meghana…

  • STAT+: On ASCO Day 4, J&J bets on Rybrevant and airs ‘innovation ecosystem’ concerns

    STAT+: On ASCO Day 4, J&J bets on Rybrevant and airs ‘innovation ecosystem’ concerns This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. ASCO ends tomorrow, but alas, dear readers,…

  • STAT+: At ASCO Day 3, AstraZeneca dominates, Takeda reveals experimental drug data, Eli Lilly serves salad

    STAT+: At ASCO Day 3, AstraZeneca dominates, Takeda reveals experimental drug data, Eli Lilly serves salad This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. We’re going to get to…

  • STAT+: AstraZeneca’s CEO balances cancer-fighting opportunities with political uncertainty

    STAT+: AstraZeneca’s CEO balances cancer-fighting opportunities with political uncertainty CHICAGO — Each year, 40,000 cancer researchers, doctors, and industry executives gather here for the biggest meeting in oncology. And for seven years, it has been almost assumed that the medicines generating the most buzz will come from AstraZeneca. Perhaps that’s why, in a wood-paneled conference…

  • STAT+: Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows

    STAT+: Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows CHICAGO — A treatment that combines two different types of cancer-fighting medicines — Gilead Sciences’ Trodelvy with Merck’s Keytruda — reduced the risk of tumor progression by more than one-third in women with an aggressive form of breast cancer. …

  • STAT+: As Trump proposes NIH cuts, a top Merck executive sees fragility in a ‘super-highway for biomedicine’

    STAT+: As Trump proposes NIH cuts, a top Merck executive sees fragility in a ‘super-highway for biomedicine’ CHICAGO — Amid ongoing uncertainty around funding for the National Institutes of Health, and what it could mean for U.S. innovation, a top Merck executive stressed that the agency is “an incredible super-highway for biomedicine,” and that it’s “a…

  • FDA approves a next-generation Covid vaccine from Moderna, with restrictions

    FDA approves a next-generation Covid vaccine from Moderna, with restrictions The Food and Drug Administration approved Moderna’s new Covid-19 vaccine late Friday, though it placed restrictions on its use that the company’s existing Covid shot, Spikevax, does not currently face. The new vaccine, which will be marketed under the name mNexspike, will not immediately replace…

  • STAT+: ASCO day 2: A tragic paradox, Gilead updates, and lots of Pfizer news

    STAT+: ASCO day 2: A tragic paradox, Gilead updates, and lots of Pfizer news This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. ASCO is usually sweltering, but it’s…

  • At ASCO 2025, attendees see reason for hope, despite worries

    At ASCO 2025, attendees see reason for hope, despite worries For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. The annual meeting of the American Society of Clinical Oncology is now in session. As always, STAT has your appetite for cancer news covered. Reporters Matt Herper, Adam…

  • Illumina’s PromoterAI unlocks rare disease clues in noncoding genome

    Illumina’s PromoterAI unlocks rare disease clues in noncoding genome Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, we discuss how one Brown contrarian and cancer researcher wants $50 billion for the NCI, we see a UniQure case study that…

  • STAT+: Up and down the ladder: The latest comings and goings

    STAT+: Up and down the ladder: The latest comings and goings Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is…

  • STAT+: RFK Jr.’s latest moves on vaccines

    STAT+: RFK Jr.’s latest moves on vaccines You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. NIH is terminating research grants left and right, impeding early career paths and leading some young scientists…

  • Moderna’s vaccine hit, the MAHA report, and an ASCO preview

    Moderna’s vaccine hit, the MAHA report, and an ASCO preview What does the MAHA Commission have planned for the drug industry? Why is Robert F. Kennedy Jr. targeting mRNA vaccines? And what are Adam and Elaine getting up to in Chicago? We discuss all that and more on this week’s episode of “The Readout LOUD,”…

  • Post-TIGIT flop, iTeos Therapeutics is shuttering

    Post-TIGIT flop, iTeos Therapeutics is shuttering Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we look at the implications of BARDA cutting a major vaccine contract with Moderna, hear why former FDA chief Scott Gottlieb thinks agency layoffs will impede…

  • STAT+: HHS cancels nearly $600 million Moderna contract on vaccines for flu pandemics

    STAT+: HHS cancels nearly $600 million Moderna contract on vaccines for flu pandemics This story will be updated The Department of Health and Human Services has notified Moderna that it is canceling a nearly $600 million contract with the company to develop, test, and license vaccines for flu strains that could trigger future pandemics, including…

  • Lilly to acquire biotech developing pain drugs

    Lilly to acquire biotech developing pain drugs Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, we’re seeking nominations for our annual Wunderkinds list, which aims to honor some of the most promising early-career scientists out there. If you have someone in mind, submit…

  • STAT+: What Baby KJ means for the CRISPR gene editing industry

    STAT+: What Baby KJ means for the CRISPR gene editing industry For the ailing gene editing industry, hope came earlier this month in the tiny, smiling, fuzzy-headed form of KJ Muldoon. At just 6 months old, KJ received a gene editing treatment custom-built to correct his unique mutation. He’s not cured, researchers explained at the…

  • STAT+: Up and down the ladder: The latest comings and goings

    STAT+: Up and down the ladder: The latest comings and goings Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is…

  • GSK drug’s new approval sets up competition with Dupixent

    GSK drug’s new approval sets up competition with Dupixent Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Apologies that this newsletter is coming late to you this morning — we had some technical difficulties. But we’ve still got the news…

  • STAT+: Merus drug, with immunotherapy, shows preliminary survival boost for patients with head and neck cancer

    STAT+: Merus drug, with immunotherapy, shows preliminary survival boost for patients with head and neck cancer Merus said Thursday that a combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda has kept 79% of patients with newly diagnosed metastatic head and cancer alive for at least one year, according to a new analysis…

  • Uncertainty in CRISPR world and the start of more M&A

    Uncertainty in CRISPR world and the start of more M&A What was the mood like at a big gene therapy conference last week? Why is Novo Nordisk’s CEO stepping down? And why has Adam been in such a good mood? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s…

  • STAT+: Five burning questions on the FDA’s new Covid-19 vaccine framework

    STAT+: Five burning questions on the FDA’s new Covid-19 vaccine framework WASHINGTON — Food and Drug Administration Commissioner Marty Makary promised stakeholders last week that the agency’s new Covid-19 vaccine framework would answer all of their questions.  But the framework has perhaps created as much confusion as clarity. Broadly, the FDA said it will limit approval…

  • STAT+: Maryland governor signs law to expand powers of the state’s prescription drug affordability board

    STAT+: Maryland governor signs law to expand powers of the state’s prescription drug affordability board In a notable development, Maryland Gov. Wes Moore signed a bill that will allow a state board to extend its mandate for lowering prescription drug costs to all residents, not just those employed by government agencies. The move was hailed…

  • Trump’s drug-pricing plan and a potential Theranos 2.0

    Trump’s drug-pricing plan and a potential Theranos 2.0 How likely is it for President Trump’s new drug-pricing plan to be implemented? Why have investors seemed unbothered by the proposal? And will we see a return of Elizabeth Holmes’ blood-testing ambitions? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s…

  • STAT+: Eli Lilly and AstraZeneca top a consultancy’s ranking of drug company R&D

    STAT+: Eli Lilly and AstraZeneca top a consultancy’s ranking of drug company R&D A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap — but when it comes to invention, AstraZeneca, with its wealth of experimental cancer and rare disease therapies, ranks above its…

  • STAT+: Trump order on drug pricing appears to issue subtle threat to pharma

    STAT+: Trump order on drug pricing appears to issue subtle threat to pharma File this under “Lower your price — or else!” Tucked inside the executive order on drug pricing from President Trump is a sentence that appears to threaten pharmaceutical companies that their medicines may be withdrawn if they do not lower prices. Specifically,…

  • STAT+: Our biggest burning questions on Trump’s order to bring down drug prices

    STAT+: Our biggest burning questions on Trump’s order to bring down drug prices WASHINGTON — President Trump’s executive order to lower drug prices through sweeping, cross-agency action left leaders in the pharmaceutical industry scrambling Monday to make sense of what may be ahead — and how to respond. The announcement was long on messaging, but…

  • STAT+: Trump’s drug-pricing order takes a hard line against pharma. Investors shrugged

    STAT+: Trump’s drug-pricing order takes a hard line against pharma. Investors shrugged President Trump on Monday unveiled his plan to dramatically overhaul the way the U.S. pays for drugs by lowering what he calls “inflated” prices to those paid by other countries. Pharma investors didn’t seem to care. The XBI, a closely tracked index of…

  • FDA approves Verastem’s ovarian cancer treatment

    FDA approves Verastem’s ovarian cancer treatment Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk about the FDA’s new artificial intelligence effort in the wake of mass layoffs, see AI darling Insitro cut staff, and more. Read the rest… Meghana…

  • STAT+: Up and down the ladder: The latest comings and goings

    STAT+: Up and down the ladder: The latest comings and goings Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is…

  • STAT+: More Medicare plans cover Humira biosimilars, but do little to encourage patient use

    STAT+: More Medicare plans cover Humira biosimilars, but do little to encourage patient use Medicare drug plans significantly boosted coverage of biosimilar versions of the Humira rheumatoid arthritis medicine this year, but nearly all of them failed to take steps that would encourage greater use of these alternative treatments, a new government watchdog report finds.…

  • A firebrand takes oversight of vaccines, gene therapies

    A firebrand takes oversight of vaccines, gene therapies What does the appointment of Vinay Prasad as the head of biologic drug evaluation mean for biotechs? Is his fiery public persona suited for government service? We discuss these and other burning questions on a new episode of “The Readout LOUD,” STAT’s biotech podcast. Read the rest……

  • STAT+: The state of antibiotic development: ‘Deplorable comes to mind’

    STAT+: The state of antibiotic development: ‘Deplorable comes to mind’ Four years ago, an ambitious pharmaceutical industry venture to tackle antibiotic resistance launched to invest in small companies that can develop two to four novel antibiotics by 2030 — and replenish the global supply chain with needed treatments. The effort began with $1 billion in backing…

  • STAT+: Few drugmakers embrace a newer test for contamination, placing horseshoe crabs at risk

    STAT+: Few drugmakers embrace a newer test for contamination, placing horseshoe crabs at risk Many large drugmakers are still using a decades-old test — derived from horseshoe crabs — as a go-to tool for detecting contamination in medicines and vaccines, rather than switching to a cheaper and equally effective alternative, according to a survey by…

  • STAT+: Vinay Prasad, in his own words, outlines the philosophy he’ll bring to the FDA

    STAT+: Vinay Prasad, in his own words, outlines the philosophy he’ll bring to the FDA People seeking roles in government are often careful about what they say in public, or at least somewhat hesitant to freely share their opinions. It’s difficult to know exactly what’s going on in their heads.  Not Vinay Prasad. The new…

  • STAT+: Trump signs order in bid to boost pharma manufacturing in the U.S.

    STAT+: Trump signs order in bid to boost pharma manufacturing in the U.S. Amid ongoing anticipation over tariffs on pharmaceuticals, President Trump on Monday signed an executive order designed to lower regulatory hurdles and make it faster for drug companies to manufacture their products in the U.S. The move also includes plans to place more…

  • STAT+: Up and down the ladder: The latest comings and goings

    STAT+: Up and down the ladder: The latest comings and goings Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is…

  • STAT+: At Stanford conference, typically guarded biotech leaders share their concerns about Trump policies

    STAT+: At Stanford conference, typically guarded biotech leaders share their concerns about Trump policies PALO ALTO, Calif. — At an annual meeting usually focused on the industry’s future, life science leaders couldn’t help but grapple — 100 days into President Trump’s second term — with a present clouded by uncertainty. At Stanford’s Drug Discovery Symposium, biotech…

  • Assessing the impact of Trump’s first 100 days on science and health policy

    Assessing the impact of Trump’s first 100 days on science and health policy On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong drug launches, and Eli Lilly’s PBM problem.  The first 100 days of the Trump administration have had a profound impact on…

  • STAT+: Lack of access to antibiotics for drug-resistant infections often blamed on poor care, study says

    STAT+: Lack of access to antibiotics for drug-resistant infections often blamed on poor care, study says Only 6.9% of people with drug-resistant infections in eight large, low- and middle-income countries received an appropriate antibiotic in 2019 and the lack of access was largely attributed to insufficient care, according to a new analysis. The researchers examined…

  • STAT+: Sales of BridgeBio’s new heart drug blow past expectations

    STAT+: Sales of BridgeBio’s new heart drug blow past expectations BridgeBio’s recently approved heart drug brought in $36.7 million in sales in the first quarter, blowing past expectations as the biotech continues to see a strong demand for its first major commercial product.  Analysts had estimated that the treatment, called Attruby, would bring in sales…

  • STAT+: What was big at AACR? A drug, a diagnostic, and a dog. Oh and a vaccine, too.

    STAT+: What was big at AACR? A drug, a diagnostic, and a dog. Oh and a vaccine, too. You’re reading the web edition of AACR in 30 Seconds, STAT’s guide to the American Association for Cancer Research annual meeting. We’d like to introduce you to the fellow above, whose name is Jae. When asked what…

  • STAT+: Capricor Therapeutics forges ahead with FDA on Duchenne drug, despite political tumult

    STAT+: Capricor Therapeutics forges ahead with FDA on Duchenne drug, despite political tumult The Food and Drug Administration is nearly halfway through a review of Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy. Even with the tumult inside the agency, interactions between the company and the agency staff have been unaffected, according to the company’s…

  • STAT+: Up and down the ladder: The latest comings and goings

    STAT+: Up and down the ladder: The latest comings and goings Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is…

  • STAT+: Caribou delays readout, discontinues programs, betting on off-the-shelf CAR-T therapies

    STAT+: Caribou delays readout, discontinues programs, betting on off-the-shelf CAR-T therapies Caribou Biosciences is delaying the readout of clinical trials involving its CRISPR T-cell therapies for blood cancer — hoping that longer follow-up will deliver enough positive data to keep the programs and the struggling biotech company alive.  The company’s decision, announced Thursday, amounts to…

  • Pharma tariffs, and a ‘sunshine day’ for biotech stocks

    Pharma tariffs, and a ‘sunshine day’ for biotech stocks How did Ireland become a hotspot for pharmaceutical manufacturing? What are the products that will come out of Flagship’s latest startup centered around “preemptive medicine”? And who among the co-hosts is the best singer? We discuss all that and more on this week’s episode of “The…

  • STAT+: Bristol’s Cobenfy disappoints as supplemental antipsychotic drug

    STAT+: Bristol’s Cobenfy disappoints as supplemental antipsychotic drug A landmark new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of standard-of-care therapy, Bristol Myers Squibb announced Tuesday. The drug, Cobenfy, was approved last year based on data from three randomized studies comparing the drug to placebo. It was the first…

  • STAT+: Biotech entrepreneur Sam Waksal accused of ‘reckless conduct’ in new lawsuit

    STAT+: Biotech entrepreneur Sam Waksal accused of ‘reckless conduct’ in new lawsuit Sam Waksal is once again in legal trouble.  The biotech entrepreneur, who was famously convicted of insider trading in 2003, allegedly breached his fiduciary duties and engaged in “grossly negligent and reckless conduct” as the chairman, CEO, and largest shareholder of Equilibre Biopharmaceuticals,…

  • STAT+: Research grants as political ammo; Death to dyes?

    STAT+: Research grants as political ammo; Death to dyes? You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. STAT won its first National Magazine Award for General Excellence. Not bad, huh? Help us…

  • STAT+: Up and down the ladder: The latest comings and goings

    STAT+: Up and down the ladder: The latest comings and goings Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is…

  • STAT+: GSK blood cancer therapy, once pulled from the market, is approved in the U.K.

    STAT+: GSK blood cancer therapy, once pulled from the market, is approved in the U.K. GSK’s blood cancer drug Blenrep won regulatory approval in the U.K. on Thursday, marking the medicine’s return to the market after it was withdrawn several years ago. The drug, which treats multiple myeloma, will be used in combination with other…

  • More proposed cuts to the NIH

    More proposed cuts to the NIH Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we talk about Arkansas making a bold move to curb PBM power, analyze Trump’s executive order in regards to drug prices, and more. Read the rest… Meghana…

  • STAT+: Trump’s plans to lower drug prices have echoes of past efforts

    STAT+: Trump’s plans to lower drug prices have echoes of past efforts WASHINGTON — The Trump administration has an expansive view for how it can lower drug prices for Americans.  It has been here before. The question is whether this time will be different. During his first term, President Trump tried to tie U.S. drug…

  • Pfizer discontinues its experimental GLP-1 pill

    Pfizer discontinues its experimental GLP-1 pill Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we discuss interesting new gene-editing data from Verve, see the NIH starting to convene advisory councils again, and more. Read the rest… Meghana Keshavan Go to statnews

  • STAT+: Up and down the ladder: The latest comings and goings

    STAT+: Up and down the ladder: The latest comings and goings Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is…

  • STAT+: FDA plans to phase out animal testing in drugs in what it calls a ‘paradigm shift’

    STAT+: FDA plans to phase out animal testing in drugs in what it calls a ‘paradigm shift’ In an unexpected move, the U.S. Food and Drug Administration announced plans this week to reduce — and possibly replace — animal testing with other methods for developing certain medicines in a bid to lower R&D costs and,…

  • BIO’s John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding

    BIO’s John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding Is there more funding coming for the biotech industry? Will the pharmaceutical industry be hit with tariffs? And is it possible to reason with RFK Jr.? We talk about all that and more on this week’s episode of “The Readout…

  • STAT+: Up and down the ladder: The latest comings and goings

    STAT+: Up and down the ladder: The latest comings and goings Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is…

  • NIH hit with chaos, cuts, and contractor purge

    NIH hit with chaos, cuts, and contractor purge Hello. Today, we dive into the implications of the ongoing cuts to various health and science agencies….It’s a doozy. Oh, and if you like talking about neuroscience and happen to be near San Diego this weekend, come hang with me and my colleagues at STAT@AAN: The Future…

  • STAT+: Makary’s first speech to FDA staff focuses on challenging norms, fighting chronic disease

    STAT+: Makary’s first speech to FDA staff focuses on challenging norms, fighting chronic disease WASHINGTON — Marty Makary’s first address to staff as FDA commissioner on Wednesday afternoon sounded a bit like an introduction to one of his books.  It included sweeping declarations about the need to challenge scientific norms, and to identify the root…

  • Emotional whiplash for PTC Therapeutics

    Emotional whiplash for PTC Therapeutics Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we process the shockwaves in biotech following the ouster of CBER chief Peter Marks, see a radiopharmaceutical expand its reach, and more. Read the rest… Meghana Keshavan…

  • Opinion: STAT+: Peter Marks’ ouster is an ominous sign for biotech — and for public health

    Opinion: STAT+: Peter Marks’ ouster is an ominous sign for biotech — and for public health Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler. There are certain leaders who quietly make complex organizations operate well including in the toughest of times — leaders like Peter Marks, director of…

  • STAT+: Ouster of FDA’s Peter Marks alarms a biopharma industry that saw him as an ally

    STAT+: Ouster of FDA’s Peter Marks alarms a biopharma industry that saw him as an ally When Robert F. Kennedy Jr., a longtime and visceral critic of pharmaceutical and biotech companies, was nominated by President Trump to be the nation’s health secretary, the head of biotech’s largest trade group issued a statement saying that he…

  • STAT+: Amgen loses its battle against Colorado over a prescription drug affordability board

    STAT+: Amgen loses its battle against Colorado over a prescription drug affordability board In a blow to the pharmaceutical industry, a U.S. court judge ruled that a Colorado state board can proceed with plans to place limits on the prices paid for medicines, the first such decision to support the controversial attempts by some states…

  • STAT+: Wyden claims Pfizer used a ‘colossal’ scheme to avoid paying billions in U.S. taxes

    STAT+: Wyden claims Pfizer used a ‘colossal’ scheme to avoid paying billions in U.S. taxes In what one U.S. lawmaker described as possibly the “largest tax-dodging scheme” by a pharmaceutical company in history, Pfizer sold $20 billion in medicines to U.S. customers six years ago, but did not report any profits from those sales on…